Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | TGM2 | P21980 | 10/20 | 0.44 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 6/20 | 0.41 |
| ▸ | ECE1 | P42892 | 1/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30849132 | 1.00 | FOLH1 (0.50) | FOLH1TGM2SLC6A5CASP1ECE1 | |
| SCHEMBL287193 | 1.00 | FOLH1 (0.50) | FOLH1TGM2SLC6A5CASP1ECE1 | |
| SCHEMBL21315776 | 0.95 | FOLH1 (0.44) | FOLH1TGM2SLC6A5CASP1 | |
| SCHEMBL7605714 | 0.95 | FOLH1 (0.44) | FOLH1TGM2SLC6A5CASP1 | |
| SCHEMBL28836164 | 0.87 | ACE (0.48) | FOLH1TGM2CASP1ECE1 | |
| SCHEMBL18100018 | 0.85 | TGM2 (0.50) | TGM2SLC6A5CASP1 | |
| SCHEMBL23705401 | 0.84 | TGM2 (0.52) | FOLH1TGM2CASP1 | |
| SCHEMBL23705400 | 0.84 | TGM2 (0.52) | FOLH1TGM2CASP1 | |
| SCHEMBL11001505 | 0.84 | CASP1 (0.45) | FOLH1TGM2CASP1 | |
| SCHEMBL1273161 | 0.84 | TGM2 (0.48) | TGM2CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 497 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325632-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | Synthorx, Inc. (US) | 2025-10-23 | — | — | US | claimed |
| US-20250325633-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | Synthorx, Inc. (US) | 2025-10-23 | — | — | US | claimed |
| EP-4539887-A1 | INTERLEUKIN-2 PRODRUGS | Merck Sharp & Dohme LLC (US) | 2025-04-23 | — | — | EP | claimed |
| CN-119708196-A | Tenipout peptide synthesis method | 深圳翰宇药业股份有限公司 | 2025-03-28 | — | — | CN | claimed |
| US-20240287151-A1 | IL-15 Conjugates and Uses Thereof | Synthorx, Inc. (US) | 2024-08-29 | — | — | US | claimed |
| US-20240158735-A1 | METHODS AND COMPOSITIONS USING AN ENGINEERED RELEASE FACTOR | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2024-05-16 | — | — | US | claimed |
| US-20240101631-A1 | HUMAN INTERLEUKIN-2 CONJUGATES BIASED FOR THE INTERLEUKIN-2 RECEPTOR BETA-GAMMAC DIMER AND CONJUGATED TO A NONPEPTIDIC, WATER-SOLUBLE POLYMER | MERCK SHARP & DOHME LLC (US) | 2024-03-28 | — | — | US | claimed |
| US-11919934-B2 | IL-15 conjugates and uses thereof | Synthorx, Inc. (US) | 2024-03-05 | — | — | US | claimed |
| WO-2023244517-A1 | INTERLEUKIN-2 PRODRUGS | MERCK SHARP & DOHME LLC (US) | 2023-12-21 | — | — | WO | claimed |
| US-20230212535-A1 | MODIFIED HELICASES | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2023-07-06 | — | — | US | claimed |
| WO-2019028419-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | Synthorx, Inc. (US) | 2019-02-07 | — | — | WO | claimed |
| US-20180037874-A9 | MODIFIED HELICASES | OXFORD NANOPORE TECHNOLOGIES LTD. (GB) | 2018-02-08 | — | — | US | claimed |
| US-20160257942-A1 | MODIFIED HELICASES | OXFORD NANOPORE TECHNOLOGIES LTD. (GB) | 2016-09-08 | — | — | US | claimed |
| EP-3058088-A2 | MODIFIED ENZYMES | Oxford Nanopore Technologies Limited (GB) | 2016-08-24 | — | — | EP | claimed |
| US-20150191709-A1 | MODIFIED HELICASES | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2015-07-09 | — | — | US | claimed |
| EP-2875128-A1 | MODIFIED HELICASES | Oxford Nanopore Technologies Limited (GB) | 2015-05-27 | — | — | EP | claimed |
| WO-2015055981-A2 | MODIFIED ENZYMES | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2015-04-23 | — | — | WO | claimed |
| US-8735093-B2 | Mutant pyrrolysyl-tRNA synthetase, and method for production of protein having non-natural amino acid integrated therein by using the same | RIKEN (JP) | 2014-05-27 | — | — | US | claimed |
| WO-2014013260-A1 | MODIFIED HELICASES | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2014-01-23 | — | — | WO | claimed |
| EP-1088020-B1 | FUNCTIONALISED POLYMERS OF ALPHA-AMINO ACIDS AND THE METHOD OF PREPARATION THEREOF | USTAV MAKROMOLEKULARNI CHEMIE (CZ) | 2002-12-18 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287151-A1 | IL-15 Conjugates and Uses Thereof | IL15, IL15RA, IL2 | FOLH1 148/4885TGM2 436/4885SLC6A5 2180/4885 |
| US-20250325633-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | IL2, IL2RA, IL15 | FOLH1 124/4885TGM2 43/4885SLC6A5 4543/4885 |
| US-20240101631-A1 | HUMAN INTERLEUKIN-2 CONJUGATES BIASED FOR THE INTERLEUKIN-2 RECEPTOR BETA-GAMMAC DIMER AND CONJUGATED TO A NONPEPTIDIC, WATER-SOLUBLE POLYMER | IL2, IL2RA, IL6ST | FOLH1 132/4885TGM2 64/4885SLC6A5 2335/4885 |
| US-20250325632-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | IL2, IL2RA, IL36G | FOLH1 169/4885TGM2 108/4885SLC6A5 4640/4885 |
| US-11919934-B2 | IL-15 conjugates and uses thereof | IL15, IL15RA, IL2 | FOLH1 148/4885TGM2 436/4885SLC6A5 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.